A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).

被引：0
|
作者：
Swaminathan, Mahesh
Dinardo, Courtney Denton
Maiti, Abhishek
Pemmaraju, Naveen
Ohanian, Maro
Daver, Naval Guastad
Garcia-Manero, Guillermo
Issa, Ghayas C.
Borthakur, Gautam
Ravandi-Kashani, Farhad
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Valero, Yesid Alvarado
Jabbour, Elias
Short, Nicholas James
Wierda, William G.
Jain, Nitin
Kornblau, Steven Mitchell
Kantarjian, Hagop M.
Konopleva, Marina
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Bellaire, TX USA
[4] Albert Einstein Coll Med, Montefiore Med Ctr, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6549
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    [J]. BLOOD, 2022, 140
  • [2] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Konopleva, Marina
    Maiti, Abhishek
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Loghavi, Sanam
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Golez, Michelle
    Pierce, Sherry A.
    Nogueras Gonzalez, Graciela M.
    Ning, Jing
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    [J]. BLOOD, 2021, 138
  • [3] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    [J]. HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [4] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    [J]. BLOOD, 2014, 124 (21)
  • [5] Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Maiti, Abhishek
    DiNardo, Courtney D.
    Cortes, Jorge E.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Naqvi, Kiran
    Ravandi, Farhad
    Alvarado, Yesid
    Short, Nicholas J.
    Daver, Naval G.
    Sasaki, Koji
    Ohanian, Maro N.
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Kornblau, Steven M.
    Masarova, Lucia
    Jain, Nitin
    Jabbour, Elias J.
    Andreeff, Michael
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Rausch, Caitlin R.
    Bivins, Carol A.
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    [J]. BLOOD, 2018, 132
  • [6] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Abaza, Yasmin
    Khan, Talha
    Dinner, Shira
    Frankfurt, Olga
    Altman, Jessica K.
    [J]. BLOOD, 2022, 140 : 9036 - 9037
  • [8] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [9] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Daver, N.
    Kantarjian, H.
    Ravandi, F.
    Estey, E.
    Wang, X.
    Garcia-Manero, G.
    Jabbour, E.
    Konopleva, M.
    O'Brien, S.
    Verstovsek, S.
    Kadia, T.
    Dinardo, C.
    Pierce, S.
    Huang, X.
    Pemmaraju, N.
    Diaz-Pines-Mateo, M.
    Cortes, J.
    Borthakur, G.
    [J]. LEUKEMIA, 2016, 30 (02) : 268 - 273
  • [10] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    N Daver
    H Kantarjian
    F Ravandi
    E Estey
    X Wang
    G Garcia-Manero
    E Jabbour
    M Konopleva
    S O'Brien
    S Verstovsek
    T Kadia
    C Dinardo
    S Pierce
    X Huang
    N Pemmaraju
    M Diaz-Pines-Mateo
    J Cortes
    G Borthakur
    [J]. Leukemia, 2016, 30 : 268 - 273
12345